1
|
Ibrahim AGE, Ciullo A, Yamaguchi S, Li C, Antes T, Jones X, Li L, Murali R, Maslennikov I, Sundararaman N, Soetkamp D, Cingolani E, Van Eyk J, Marbán E. A novel micropeptide, Slitharin, exerts cardioprotective effects in myocardial infarction. Proteomics Clin Appl 2024:e2300128. [PMID: 38444254 DOI: 10.1002/prca.202300128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 02/19/2024] [Accepted: 02/21/2024] [Indexed: 03/07/2024]
Abstract
PURPOSE Micropeptides are an emerging class of proteins that play critical roles in cell signaling. Here, we describe the discovery of a novel micropeptide, dubbed slitharin (Slt), in conditioned media from Cardiosphere-derived cells (CDCs), a therapeutic cardiac stromal cell type. EXPERIMENTAL DESIGN We performed mass spectrometry of peptide-enriched fractions from the conditioned media of CDCs and a therapeutically inert cell type (human dermal fibrobasts). We then evaluated the therapeutic capacity of the candidate peptide using an in vitro model of cardiomyocyte injury and a rat model of myocardial infarction. RESULTS We identified a novel 24-amino acid micropeptide (dubbed Slitharin [Slt]) with a non-canonical leucine start codon, arising from long intergenic non-coding (LINC) RNA 2099. Neonatal rat ventricular myocytes (NRVMs) exposed to Slt were protected from hypoxic injury in vitro compared to a vehicle or scrambled control. Transcriptomic analysis of cardiomyocytes exposed to Slt reveals cytoprotective capacity, putatively through regulation of stress-induced MAPK-ERK. Slt also exerted cardioprotective effects in rats with myocardial infarction as shown by reduced infarct size 48 h post-injury. Conclusions and clinical relavance: Thus, Slt is a non-coding RNA-derived micropeptide, identified in the extracellular space, with a potential cardioprotective function.
Collapse
Affiliation(s)
- Ahmed G E Ibrahim
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Alessandra Ciullo
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Shukuro Yamaguchi
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Chang Li
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Travis Antes
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Xaviar Jones
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Liang Li
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Ramachandran Murali
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | | | - Niveda Sundararaman
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Daniel Soetkamp
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Eugenio Cingolani
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Jennifer Van Eyk
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Eduardo Marbán
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| |
Collapse
|
2
|
Clouthier KL, Taylor AC, Xuhuai J, Liu Y, Parker S, Van Eyk J, Reddy S. A Noninvasive Circulating Signature of Combined Right Ventricular Pressure and Volume Overload in Tetralogy of Fallot/Pulmonary Atresia/Major Aortopulmonary Collateral Arteries. World J Pediatr Congenit Heart Surg 2024; 15:162-173. [PMID: 38128927 DOI: 10.1177/21501351231213626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
Background: Despite surgical advances, children with tetralogy of Fallot/pulmonary atresia/major aortopulmonary collaterals (TOF/PA/MAPCAs) are subject to chronic right ventricular (RV) pressure and volume overload. Current diagnostic tools do not identify adverse myocardial remodeling and cannot predict progression to RV failure. We sought to identify a noninvasive, circulating signature of the systemic response to right heart stress to follow disease progression. Methods: Longitudinal data were collected from patients with TOF/PA/MAPCAs (N = 5) at the time of (1) early RV pressure overload and (2) late RV pressure and volume overload. Plasma protein and microRNA expression were evaluated using high-throughput data-independent mass spectroscopy and Agilent miR Microarray, respectively. Results: At the time of early RV pressure overload, median patient age was 0.34 years (0.02-9.37), with systemic RV pressures, moderate-severe hypertrophy, and preserved systolic function. Late RV pressure and volume overload occurred at a median age of 4.08 years (1.51-10.83), with moderate RV hypertrophy and dilation, and low normal RV function; 277 proteins were significantly dysregulated (log2FC ≥0.6/≤-0.6, FDR≤0.05), predicting downregulation in lipid transport (apolipoproteins), fibrinolytic system, and extracellular matrix structural proteins (talin 1, profilin 1); and upregulation in the respiratory burst. Increasing RV size and decreasing RV function correlated with decreasing structural protein expression. Similarly, miR expression predicted downregulation of extracellular matrix-receptor interactions and upregulation in collagen synthesis. Conclusion: To our knowledge, we show for the first time a noninvasive protein and miR signature reflecting the systemic response to adverse RV myocardial remodeling in TOF/PA/MAPCAs which could be used to follow disease progression.
Collapse
Affiliation(s)
- Katie L Clouthier
- Department of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, USA
| | - Anne C Taylor
- Department of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, USA
| | - Ji Xuhuai
- Human Immune Monitoring Center and Functional Genomics Facility, Stanford University, Palo Alto, CA, USA
| | - Yuhan Liu
- Department of Medicine (Quantitative Science Unit), Stanford University, Palo Alto, CA, USA
| | - Sarah Parker
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Jennifer Van Eyk
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Sushma Reddy
- Department of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, USA
- Cardiovascular Institute, Stanford University, Los Angeles, CA, USA
| |
Collapse
|
3
|
Kreimer S, Binek A, Chazarin B, Cho JH, Haghani A, Hutton A, Marbán E, Mastali M, Meyer JG, Mesquita T, Song Y, Van Eyk J, Parker S. High-Throughput Single-Cell Proteomic Analysis of Organ-Derived Heterogeneous Cell Populations by Nanoflow Dual-Trap Single-Column Liquid Chromatography. Anal Chem 2023. [PMID: 37289937 DOI: 10.1021/acs.analchem.3c00213] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Identification and proteomic characterization of rare cell types within complex organ-derived cell mixtures is best accomplished by label-free quantitative mass spectrometry. High throughput is required to rapidly survey hundreds to thousands of individual cells to adequately represent rare populations. Here we present parallelized nanoflow dual-trap single-column liquid chromatography (nanoDTSC) operating at 15 min of total run time per cell with peptides quantified over 11.5 min using standard commercial components, thus offering an accessible and efficient LC solution to analyze 96 single cells per day. At this throughput, nanoDTSC quantified over 1000 proteins in individual cardiomyocytes and heterogeneous populations of single cells from the aorta.
Collapse
Affiliation(s)
- Simion Kreimer
- Advanced Clinical Biosystems Research Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
| | - Aleksandra Binek
- Advanced Clinical Biosystems Research Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
| | - Blandine Chazarin
- Advanced Clinical Biosystems Research Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
| | - Jae Hyung Cho
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
| | - Ali Haghani
- Advanced Clinical Biosystems Research Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
| | - Alexandre Hutton
- Advanced Clinical Biosystems Research Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California 90069, United States
| | - Eduardo Marbán
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
| | - Mitra Mastali
- Advanced Clinical Biosystems Research Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
| | - Jesse G Meyer
- Advanced Clinical Biosystems Research Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California 90069, United States
| | - Thassio Mesquita
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
| | - Yang Song
- Advanced Clinical Biosystems Research Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
| | - Jennifer Van Eyk
- Advanced Clinical Biosystems Research Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
| | - Sarah Parker
- Advanced Clinical Biosystems Research Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States
| |
Collapse
|
4
|
Muranaka H, Hendifar A, Osipov A, Moshayedi N, Placencio-Hickok V, Tatonetti N, Stotland A, Parker S, Van Eyk J, Pandol SJ, Bhowmick NA, Gong J. Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer. Cancers (Basel) 2023; 15:3020. [PMID: 37296982 PMCID: PMC10252041 DOI: 10.3390/cancers15113020] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Revised: 05/26/2023] [Accepted: 05/30/2023] [Indexed: 06/12/2023] Open
Abstract
Pancreatic cancer (PC) is one of the deadliest cancers. Developing biomarkers for chemotherapeutic response prediction is crucial for improving the dismal prognosis of advanced-PC patients (pts). To evaluate the potential of plasma metabolites as predictors of the response to chemotherapy for PC patients, we analyzed plasma metabolites using high-performance liquid chromatography-mass spectrometry from 31 cachectic, advanced-PC subjects enrolled into the PANCAX-1 (NCT02400398) prospective trial to receive a jejunal tube peptide-based diet for 12 weeks and who were planned for palliative chemotherapy. Overall, there were statistically significant differences in the levels of intermediates of multiple metabolic pathways in pts with a partial response (PR)/stable disease (SD) vs. progressive disease (PD) to chemotherapy. When stratified by the chemotherapy regimen, PD after 5-fluorouracil-based chemotherapy (e.g., FOLFIRINOX) was associated with decreased levels of amino acids (AAs). For gemcitabine-based chemotherapy (e.g., gemcitabine/nab-paclitaxel), PD was associated with increased levels of intermediates of glycolysis, the TCA cycle, nucleoside synthesis, and bile acid metabolism. These results demonstrate the feasibility of plasma metabolomics in a prospective cohort of advanced-PC patients for assessing the effect of enteral feeding as their primary source of nutrition. Metabolic signatures unique to FOLFIRINOX or gemcitabine/nab-paclitaxel may be predictive of a patient's response and warrant further study.
Collapse
Affiliation(s)
- Hayato Muranaka
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; (H.M.); (A.H.); (A.O.); (N.M.); (V.P.-H.); (S.J.P.); (N.A.B.)
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Andrew Hendifar
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; (H.M.); (A.H.); (A.O.); (N.M.); (V.P.-H.); (S.J.P.); (N.A.B.)
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Arsen Osipov
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; (H.M.); (A.H.); (A.O.); (N.M.); (V.P.-H.); (S.J.P.); (N.A.B.)
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Natalie Moshayedi
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; (H.M.); (A.H.); (A.O.); (N.M.); (V.P.-H.); (S.J.P.); (N.A.B.)
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Veronica Placencio-Hickok
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; (H.M.); (A.H.); (A.O.); (N.M.); (V.P.-H.); (S.J.P.); (N.A.B.)
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Nicholas Tatonetti
- Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA;
| | - Aleksandr Stotland
- Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; (A.S.); (S.P.); (J.V.E.)
| | - Sarah Parker
- Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; (A.S.); (S.P.); (J.V.E.)
| | - Jennifer Van Eyk
- Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; (A.S.); (S.P.); (J.V.E.)
| | - Stephen J. Pandol
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; (H.M.); (A.H.); (A.O.); (N.M.); (V.P.-H.); (S.J.P.); (N.A.B.)
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Neil A. Bhowmick
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; (H.M.); (A.H.); (A.O.); (N.M.); (V.P.-H.); (S.J.P.); (N.A.B.)
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
- Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
| | - Jun Gong
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; (H.M.); (A.H.); (A.O.); (N.M.); (V.P.-H.); (S.J.P.); (N.A.B.)
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| |
Collapse
|
5
|
Gatto L, Aebersold R, Cox J, Demichev V, Derks J, Emmott E, Franks AM, Ivanov AR, Kelly RT, Khoury L, Leduc A, MacCoss MJ, Nemes P, Perlman DH, Petelski AA, Rose CM, Schoof EM, Van Eyk J, Vanderaa C, Yates JR, Slavov N. Initial recommendations for performing, benchmarking and reporting single-cell proteomics experiments. Nat Methods 2023; 20:375-386. [PMID: 36864200 PMCID: PMC10130941 DOI: 10.1038/s41592-023-01785-3] [Citation(s) in RCA: 37] [Impact Index Per Article: 37.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Accepted: 01/24/2023] [Indexed: 03/04/2023]
Abstract
Analyzing proteins from single cells by tandem mass spectrometry (MS) has recently become technically feasible. While such analysis has the potential to accurately quantify thousands of proteins across thousands of single cells, the accuracy and reproducibility of the results may be undermined by numerous factors affecting experimental design, sample preparation, data acquisition and data analysis. We expect that broadly accepted community guidelines and standardized metrics will enhance rigor, data quality and alignment between laboratories. Here we propose best practices, quality controls and data-reporting recommendations to assist in the broad adoption of reliable quantitative workflows for single-cell proteomics. Resources and discussion forums are available at https://single-cell.net/guidelines .
Collapse
Affiliation(s)
- Laurent Gatto
- Computational Biology and Bioinformatics Unit, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
| | - Ruedi Aebersold
- Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
| | - Juergen Cox
- Max Planck Institute of Biochemistry, Martinsried, Germany
| | | | - Jason Derks
- Departments of Bioengineering, Biology, Chemistry and Chemical Biology, Single-Cell Proteomics Center and Barnett Institute, Northeastern University, Boston, MA, USA
| | - Edward Emmott
- Centre for Proteome Research, Department of Biochemistry and Systems Biology, University of Liverpool, Liverpool, UK
| | - Alexander M Franks
- Department of Statistics and Applied Probability, University of California Santa Barbara, Santa Barbara, CA, USA
| | - Alexander R Ivanov
- Department of Chemistry and Chemical Biology, Barnett Institute of Chemical and Biological Analysis, Northeastern University, Boston, MA, USA
| | - Ryan T Kelly
- Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA
| | - Luke Khoury
- Departments of Bioengineering, Biology, Chemistry and Chemical Biology, Single-Cell Proteomics Center and Barnett Institute, Northeastern University, Boston, MA, USA
| | - Andrew Leduc
- Departments of Bioengineering, Biology, Chemistry and Chemical Biology, Single-Cell Proteomics Center and Barnett Institute, Northeastern University, Boston, MA, USA
| | | | - Peter Nemes
- Department of Chemistry and Biochemistry, University of Maryland, College Park, MD, USA
| | - David H Perlman
- Merck Exploratory Science Center, Merck Sharp & Dohme Corp., Cambridge, MA, USA
| | - Aleksandra A Petelski
- Departments of Bioengineering, Biology, Chemistry and Chemical Biology, Single-Cell Proteomics Center and Barnett Institute, Northeastern University, Boston, MA, USA
- Parallel Squared Technology Institute, Watertown, MA, USA
| | - Christopher M Rose
- Department of Microchemistry, Proteomics and Lipidomics, Genentech Inc., South San Francisco, CA, USA
| | - Erwin M Schoof
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark
| | | | - Christophe Vanderaa
- Computational Biology and Bioinformatics Unit, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
| | - John R Yates
- Departments of Molecular Medicine and Neurobiology, the Scripps Research Institute, La Jolla, CA, USA
| | - Nikolai Slavov
- Departments of Bioengineering, Biology, Chemistry and Chemical Biology, Single-Cell Proteomics Center and Barnett Institute, Northeastern University, Boston, MA, USA.
- Parallel Squared Technology Institute, Watertown, MA, USA.
| |
Collapse
|
6
|
Jani VP, Yoo E, Binek A, Guo A, Aslam I, Sharma K, Van Eyk J, Hahn V, Kass DA. Proteomic signatures predict depressed cooperativity and increased calcium sensitivity in heart failure with preserved ejection fraction. Biophys J 2023; 122:406a. [PMID: 36784071 DOI: 10.1016/j.bpj.2022.11.2209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023] Open
Affiliation(s)
- Vivek P Jani
- Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Edwin Yoo
- Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Aleksandra Binek
- Advanced Clinical Biosystems Institute, Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
| | - Alina Guo
- Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Imran Aslam
- School of Medicine, University of Texas San Antonio, San Antonio, TX, USA
| | - Kavita Sharma
- Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Jennifer Van Eyk
- Advanced Clinical Biosystems Institute, Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
| | - Virginia Hahn
- Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - David A Kass
- Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
7
|
Berdyshev E, Kim J, Goleva E, Bronova I, Bronoff AS, Lyubchenko T, Kreimer S, Van Eyk J, Kim BE, Leung D, Ahn K. Stratum corneum lipid biomarkers at two months of age predict future onset of atopic dermatitis. J Allergy Clin Immunol 2023. [DOI: 10.1016/j.jaci.2022.12.603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
8
|
Kreimer S, Binek A, Chazarin B, Cho JH, Haghani A, Hutton A, Marb√°n E, Mastali M, Meyer JG, Ribiero Mesquita TR, Song Y, Van Eyk J, Parker S. High Throughput Single Cell Proteomic Analysis of Organ Derived Heterogeneous Cell Populations by Nanoflow Dual Trap Single Column Liquid Chromatography. bioRxiv 2023:2023.01.06.522908. [PMID: 36711540 PMCID: PMC9881989 DOI: 10.1101/2023.01.06.522908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Identification and proteomic characterization of rare cell types within complex organ derived cell mixtures is best accomplished by label-free quantitative mass spectrometry. High throughput is required to rapidly survey hundreds to thousands of individual cells to adequately represent rare populations. Here we present parallelized nanoflow dual-trap single-column liquid chromatography (nanoDTSC) operating at 15 minutes of total run time per cell with peptides quantified over 11.5 minutes using standard commercial components, thus offering an accessible and efficient LC solution to analyze 96 single-cells per day. At this throughput, nanoDTSC quantified over 1,000 proteins in individual cardiomyocytes and heterogenous populations of single cells from aorta.
Collapse
|
9
|
DeWitt ME, Herrington DM, Williamson JC, Seals AL, Wierzba TF, Binek A, Van Eyk J, Sanders JW. 530. Characterization of the Proteomic Changes via SARS-CoV-2 Infection or Vaccination in the COVID-19 Community Research Partnership (CCRP). Open Forum Infect Dis 2022. [DOI: 10.1093/ofid/ofac492.585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Abstract
Background
There remain important gaps in knowledge concerning the effects of SARS-CoV-2 infection or vaccination on the human blood proteome.
Methods
The CCRP is a longitudinal surveillance study with information on SARS-CoV-2 infections, vaccinations and associated humoral immune responses in over 37,000 individuals. We selected a sample of blood spots cards (n=510) from serum antibody studies obtained between October 2020 and April 2021 for mass spectrometry proteomics analysis covering 540 unique plasma proteins. We analyzed the quantified protein differences based on dried blood samples obtained before and after infection or vaccination among previously non-infected individuals (immune naïve) after adjustment for batch effects, age, sex, or prior diagnosis of cancer, cardiovascular or autoimmune disease, or diabetes. The majority of infected individuals were minimally symptomatic. Differentially expressed proteins were considered significant with an FDR adjusted p-value of < 0.05 and log2 fold change (L2FC) >0.2.
Results
We found 11 and 12 proteins differentially expressed proteins in the naïve/infected and naïve/vaccinated people respectively, of which 10 were shared. Hepatocyte growth factor receptor (HGF) was upregulated (L2FC 0.24; p < 0.001) only in those who were infected while fibrillarin (L2FC -0.24; p< 0.001) and lambda-crystallin homolog (L2FC -0.29, p < 0.001) were downregulated only in the vaccinated samples (Fig 1). The remaining DE protein were associated with a wide array of functions including metabolic, cytostructural, extracellular matrix and DNA regulatory processes.
Conclusion
We found changes in the proteome both from infection and vaccination. HGF, elevated in the infected, has been associated with endothelial inflammation, upregulation of pro-inflammatory cytokines to reduce lung fibrosis and is known to promote tissue repair. Fibrillarin, downregulated in the vaccinated, has been associated with higher rates of bacterial and viral clearance, inflammation reduction, and increased cell survival. These findings suggest detectable complex inflammation from mild to moderate infections. Further investigation is required to understand the mechanism of action and clinical implication of these findings.
Disclosures
All Authors: No reported disclosures.
Collapse
Affiliation(s)
- Michael E DeWitt
- Atrium Wake Forest Baptist Health/ Wake Forest University School of Medicine , Winston-Salem, North Carolina
| | - David M Herrington
- Wake Forest university School of Medicne , Winston Salem, North Carolina
| | | | | | - Thomas F Wierzba
- Wake Forest University School of Medicine , Winston-Salem, North Carolina
| | | | | | - John W Sanders
- Wake Forest University School of Medicine , Winston-Salem, North Carolina
| |
Collapse
|
10
|
Park E, Ito K, Iqbal R, Amigues I, Bokhari S, Van Eyk J, Depender C, Giles JT, Bathon J. Prospective changes in diastolic function in patients with rheumatoid arthritis. Arthritis Res Ther 2022; 24:184. [PMID: 35932048 PMCID: PMC9354314 DOI: 10.1186/s13075-022-02864-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 07/02/2022] [Indexed: 11/21/2022] Open
Abstract
Background Diastolic dysfunction (DD) is more prevalent in patients with rheumatoid arthritis (RA) compared to the general population. However, its evolution over time and its significant clinical predictors remain uncharacterized. We report on baseline and prospective changes in diastolic function and its associated RA and cardiovascular (CV) predictors. Methods In this study, 158 RA patients without clinical CV disease (CVD) were enrolled and followed up at 4 to 6 years, undergoing baseline and follow-up echocardiography to assess for DD, as well as extensive characterization of RA disease activity and CV risk factors. Novel measures of myocardial inflammation and perfusion were obtained at baseline only. Using baseline and follow-up composite DD (E/e′, Left Atrial Volume Index (LAVI) or peak tricuspid regurgitation (TR) velocity; ≥ 1 in top 25%) as the outcome, multivariable regression models were constructed to identify predictors of DD. Results DD was prevalent in RA patients without clinical heart failure (HF) (40.7% at baseline) and significantly progressed on follow-up (to 57.9%). Baseline composite DD was associated with baseline RA disease activity (Clinical Disease Activity Index; CDAI) (OR 1.39; 95% CI 1.02–1.90; p=0.034). Several individual diastolic parameters (baseline E/e′ and LAVI) were associated with troponin-I and brain natriuretic peptide (BNP). Baseline and follow-up composite DD, however, were not associated with myocardial inflammation, myocardial microvascular dysfunction, or subclinical atherosclerosis. Conclusions DD is prevalent in RA patients without clinical HF and increases to >50% over time. Higher RA disease activity at baseline predicted baseline composite DD. Future longitudinal studies should explore whether adverse changes in diastolic function lead to clinical HF and are attenuated by disease-modifying antirheumatic drugs (DMARDs). Supplementary Information The online version contains supplementary material available at 10.1186/s13075-022-02864-0.
Collapse
Affiliation(s)
- Elizabeth Park
- Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center/New York Presbyterian Hospital, 630 W 168th St, P&S 3-450, New York, NY, 10032, USA.
| | - Kazato Ito
- Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons and New York Presbyterian Hospital, New York, NY, USA
| | - Rabia Iqbal
- Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center/New York Presbyterian Hospital, 630 W 168th St, P&S 3-450, New York, NY, 10032, USA
| | - Isabelle Amigues
- Division of Rheumatology, National Jewish Health, Denver, CO, USA
| | - Sabahat Bokhari
- Lehigh Valley Heart and Vascular Institute, Allentown, PA, USA
| | - Jennifer Van Eyk
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Christopher Depender
- Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center/New York Presbyterian Hospital, 630 W 168th St, P&S 3-450, New York, NY, 10032, USA
| | - Jon T Giles
- Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center/New York Presbyterian Hospital, 630 W 168th St, P&S 3-450, New York, NY, 10032, USA
| | - Joan Bathon
- Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center/New York Presbyterian Hospital, 630 W 168th St, P&S 3-450, New York, NY, 10032, USA
| |
Collapse
|
11
|
Osipov A, Nikolic O, Gertych A, Parker S, Mota J, Bebawy M, Dagliyan G, Rosser CJ, Singh P, Filippova D, Huynh CA, Yuan X, Tourtellotte W, Van Eyk J, Theodorescu D. The Molecular Twin platform: a novel machine learning tool for democratization of precision cancer medicine. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e13546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13546 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers. Contemporary analyses focused on a handful of molecular and clinical variables combined with machine learning algorithms (MLA) are unable to accurately predict therapy outcomes. Here, we use the Molecular Twin multi-omic analytical platform that evaluates tumor and host features extracted from 10 multi-omic analytes and provides an array of MLA, including a Parsimonious Biomarker Model that can predict survival and recurrence with limited analytic burden, while maintaining a high degree of fidelity. Methods: Retrospectively collected serum and tissue samples from 74 patients with Stage I/II resectable PDAC were subjected to targeted NGS DNA sequencing, whole transcriptome RNA sequencing, paired tissue proteomics, unpaired serum proteomics, lipidomics and computational pathology. Analytes including plasma proteins, RNA fusions, tissue proteins, plasma lipids, RNA gene expressions, CNVs, INDELS, SNVs and tumor nuclei characteristics, were processed to obtain a panel of 6363 features. 1024 single-omic and multi-omics feature combinations generated from this panel served as input for 7 different types of MLA to predict binary survival (SR) and disease recurrence (DR) outcomes. The resultant 70 single and 7098 multi-omic biomarker models were evaluated for positive predictive value (PPV) and accuracy (ACC) in predicting DR and SR, and feature proportions learned by each ML model using leave-one-patient-out cross-validation strategy. By recursively eliminating features with low importance, we developed progressively parsimonious biomarker models for predicting SR and DR. Results: Our top model was multi-omic and predicted the SR with ACC = 0.85, PPV = 0.87 and the DR with ACC = 0.90, and PPV = 0.91. It outperformed all models based only on one single analyte type including plasma protein, RNA fusion, tissue protein, plasma lipid, clinical, RNA gene expression, tumor nuclei characteristics, CNV, INDEL and SNV, in predicting the SR. This model contained predominantly plasma protein features. Interestingly, less accurate models contained a greater proportion of other features in addition to plasma proteins. Parsimonious feature reduction of the top model stabilized at 589 features yielding an ACC = 0.85, and PPV = 0.85, comparable to the intact model. Conclusions: This proof-of-concept of the Molecular Twin precision medicine platform applied in PDAC reveals the potential of our unique MLA to provide a novel parsimonious biomarker panel with similar fidelity as much larger biomarker panels. If these results are reproduced on larger datasets, across tumor types, the Molecular Twin platform would have significant potential to democratize precision cancer medicine by discovering smaller biomarker panels with the predictive performance of much larger ones thus reducing cost and simplifying assays.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Xiaopu Yuan
- Cedars-Sinai Medical Center, Los Angeles, CA
| | | | | | - Dan Theodorescu
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
| |
Collapse
|
12
|
Akinsola R, Muranaka H, Hendifar AE, Osipov A, Moshayedi N, Thomassian S, Stotland A, Parker S, Van Eyk J, Devkota S, Bhowmick N, Gong J. Metabolomics in advanced pancreatic cancer (PC) patients (pts) achieving weight stability on enteral feeding for cachexia. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e16291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16291 Background: We previously showed that enteral feeding was associated with weight stability and compositional changes in the gut microbiome with increased abundance of the gram-negative genera Veillonella over time. Here, we evaluated the potential of plasma metabolites as predictors of weight stability and high Veillonella abundance in enteral fed pts. Methods: The PANCAX-1 (NCT02400398) prospective trial enrolled 31 cachectic advanced PC pts to receive jejunal tube peptide-based diet for 12 weeks (wks) who were planned for standard chemotherapy. In preplanned exploratory analyses, serial blood samples were collected over 12 wks of enteral feeding. Up to 219 plasma metabolites were analyzed by mass spectrometry and high-performance liquid chromatography. Analytes were compared by relative area under the curve (AUC) and differences evaluated by two-sample t-tests. Pts were stratified by weight stable (WS, defined as weight change < 0.1 kg/baseline BMI-unit over 12 wks of enteral feeding) vs. weight unstable (WU) and high (HV) vs. low Veillonella (LV) abundance (defined by dichotomizing at the mean relative abundance in WS pts). Results: Of 31 cachectic pts enrolled into PANCAX-1, a total of 55 blood samples were collected from 28 pts for plasma metabolomics. Out of 16 evaluable pts, 62.5% receiving enteral feeding met the primary endpoint of weight stability at 12 wks. Plasma metabolomics in 10 pts showed that WU pts (n = 4) had significantly decreased levels of essential amino acids (AAs, L-histidine, L-phenylalanine) and non-essential AAs (L-citrulline, L-tyrosine, all p < 0.05) than WS pts (n = 6) at the end of 12 wks of enteral feeding. In 7 WS pts with complete serial sets of blood samples available, enteral feeding over 12 wks was associated with increases in markers of muscle mass (creatinine) but decreases in nucleotide precursors (all p < 0.05) compared to baseline. Comparison of baseline metabolites between 6 WS pts with HV and 4 WU pts with LV showed that HV was associated with increases in the nucleotide dCDP and essential AA L-isoleucine but decreased TCA cycle metabolite alpha-ketoglutarate (all p < 0.05). Decreases in lactic acid was observed at 12 wks of enteral feeding in HV pts when compared to baseline (p < 0.05). Conclusions: Our findings are hypothesis-generating in that metabolites unique to weight stability and Veillonella abundance may inform future studies of anti-cachexia therapies involving enteral feeding or microbial modulation.
Collapse
Affiliation(s)
| | | | | | - Arsen Osipov
- Johns Hopkins University School of Medicine, Department of Oncology, Balimore, MD
| | | | | | | | | | | | | | - Neil Bhowmick
- Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA
| | | |
Collapse
|
13
|
Nakamura K, Norby FL, Fu Q, Venkatraman V, mastali M, Reinier K, Van Eyk J, Chugh SS. PO-671-01 NOVEL PROTEIN BIOMARKERS FOR SUDDEN CARDIAC DEATH. Heart Rhythm 2022. [DOI: 10.1016/j.hrthm.2022.03.414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
Washington K, Marano P, Chazarin B, Maughan J, Obrutu O, Tjoe B, Herscovici R, Moy P, Shufelt C, Rutledge T, Wei J, Van Eyk J, Merz CNB. REMOTE MICROSAMPLE BLOOD COLLECTION AND PROTEOMIC ANALYSIS OF PATIENTS WITH PRIOR TAKOTSUBO CARDIOMYOPATHY SHOWS PROFILE DISTINCT FROM NORMAL CONTROLS. J Am Coll Cardiol 2022. [DOI: 10.1016/s0735-1097(22)03024-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Muranaka H, Moshayedi N, Hendifar AE, Osipov A, Placencio-Hickok V, Stotland A, Parker S, Van Eyk J, Bhowmick N, Gong J. Plasma metabolomics to predict chemotherapy (CTX) response in advanced pancreatic cancer (PC) patients (pts) on enteral feeding for cachexia. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.4_suppl.600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
600 Background: We evaluated the potential of plasma metabolites as predictors of response to CTX in a prospective cohort of pts who received enteral feeding for cachexia and advanced PC. Methods: The PANCAX-1 (NCT02400398) prospective trial enrolled 31 cachectic advanced PC pts to receive jejunal tube peptide-based diet for 12 weeks (wks) who were planned for palliative CTX. Out of 16 evaluable pts, 62.5% receiving enteral feeding met the primary endpoint of weight stability at 12 wks. As part of an exploratory analysis of the PANCAX-1 trial, serial blood samples were collected at 3 predefined timepoints over 12 wks of enteral feeding. Up to 219 plasma metabolites were analyzed by mass spectrometry and high-performance liquid chromatography. Analytes were compared by relative area under the curve (AUC) and differences evaluated by two-sample t-tests. The mean AUC was used in pts with metabolites measured from > 1 timepoint of collection. Pts were stratified by stable disease (SD), partial response (PR), or progressive disease (PD) as best overall response to standard CTX. Results: Of 31 pts with advanced PC prospectively enrolled for enteral feeding, there were 55 blood samples collected from 28 pts available for plasma metabolomics. 20/28 (71%) pts received first-line CTX, the majority of whom (90%) received gemcitabine-based CTX. There were 2 PRs (7%) and 10 with SD (36%) as best response to CTX. Overall, there were statistically significant differences in levels of intermediates involved in multiple metabolic pathways including glycolysis, the tricarboxylic acid (TCA) cycle, fatty acid synthesis, and nucleoside synthesis in pts with PR/SD vs. PD to CTX (all p < 0.05). When stratified by CTX regimen, PD to 5-fluorouracil-based CTX (e.g., FOLFIRINOX) was associated with decreased levels of essential amino acids (AAs, L-leucine, L-methionine, L-tryptophan) and non-essential AAs (L-arginine, L-serine, L-tyrosine, all p < 0.05). For gemcitabine-based CTX (e.g., gemcitabine/nab-paclitaxel), PD was associated with increased levels of intermediates of glycolysis (pyruvate), TCA cycle (L-glutamate), nucleoside synthesis (xanthine), and bile acid metabolism (taurocholic acid, all p < 0.05). Conclusions: We are the first to demonstrate the feasibility of plasma metabolomics in a prospective cohort of advanced PC pts on enteral feeding as their primary source of nutrition. Metabolic signatures unique to FOLFIRINOX or gemcitabine/nab-paclitaxel may be predictive of response and warrant further study.
Collapse
Affiliation(s)
| | | | | | - Arsen Osipov
- Johns Hopkins University School of Medicine, Department of Oncology, Balimore, MD
| | | | | | | | | | - Neil Bhowmick
- Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA
| | | |
Collapse
|
16
|
Stachowicz A, Sundararaman N, Venkatraman V, Van Eyk J, Fert-Bober J. pH/Acetonitrile-Gradient Reversed-Phase Fractionation of Enriched Hyper-Citrullinated Library in Combination with LC-MS/MS Analysis for Confident Identification of Citrullinated Peptides. Methods Mol Biol 2021; 2420:107-126. [PMID: 34905169 DOI: 10.1007/978-1-0716-1936-0_9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Citrullination, the Ca2+-driven enzymatic conversion of arginine residues to citrulline, is a posttranslational modification, implicated in several physiological and pathological processes. Several methods to detect citrullinated proteins have been developed, including color development reagent, fluorescence, phenylglyoxal, and antibody-based methods. These methods yet suffer from limitations in sensitivity, specificity, or citrullinated site determination. Mass spectrometry (MS)-based proteomic analysis has emerged as a promising method to resolve these problems. However, due to low abundance of citrullinated proteins and similar MS features to deamidation of asparagine and glutamine, confident identification of citrullinated proteome is challenging. Here, we present a systematic approach to identify a compendium of steps to enhance the number of detected citrullinated residue and implement diagnostic MS feature that allow the confidence of MS-based identifications. Our method is based on the concept of generation of hyper-citrullinated library with high-pH reversed-phase peptide fractionation that allows to enrich in low abundance citrullinated peptides and amplify the effect of charge loss upon citrullination. Application of our approach to complex global citrullino-proteome datasets demonstrates the confident assessment of citrullinated peptides, thereby enhancing the size and functional interpretation of citrullinated proteomes.
Collapse
Affiliation(s)
- Aneta Stachowicz
- Cedars-Sinai Medical Center, Smidt Heart Institute, Advanced Clinical Biosystems Research Institute, Los Angeles, CA, USA
- Chair of Pharmacology, Jagiellonian University Medical College, Institute of Pharmacology, Krakow, Poland
| | - Niveda Sundararaman
- Cedars-Sinai Medical Center, Advanced Clinical Biosystems Research Institute, Precision Biomarker Laboratories, Los Angeles, CA, USA
| | - Vidya Venkatraman
- Cedars-Sinai Medical Center, Advanced Clinical Biosystems Research Institute, Precision Biomarker Laboratories, Los Angeles, CA, USA
| | - Jennifer Van Eyk
- Cedars-Sinai Medical Center, Smidt Heart Institute, Advanced Clinical Biosystems Research Institute, Los Angeles, CA, USA
- Cedars-Sinai Medical Center, Advanced Clinical Biosystems Research Institute, Precision Biomarker Laboratories, Los Angeles, CA, USA
| | - Justyna Fert-Bober
- Cedars-Sinai Medical Center, Smidt Heart Institute, Advanced Clinical Biosystems Research Institute, Los Angeles, CA, USA.
| |
Collapse
|
17
|
Figueiredo JC, Merin NM, Hamid O, Choi SY, Lemos T, Cozen W, Nguyen N, Finster LJ, Foley J, Darrah J, Gong J, Paquette R, Mita AC, Vescio R, Mehmi I, Basho R, Tourtellotte WG, Huynh CA, Melmed GY, Braun J, McGovern DPB, Mengesha E, Botwin G, Prostko JC, Frias EC, Stewart JL, Joung S, Van Eyk J, Ebinger JE, Cheng S, Sobhani K, Reckamp KL, Merchant A. Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. Cancer Res 2021; 81:6273-6280. [PMID: 34759001 PMCID: PMC9060668 DOI: 10.1158/0008-5472.can-21-3554] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 11/08/2021] [Accepted: 11/08/2021] [Indexed: 11/16/2022]
Abstract
Longitudinal studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine-induced immune responses in patients with cancer are needed to optimize clinical care. In a prospective cohort study of 366 (291 vaccinated) patients, we measured antibody levels [anti-spike (IgG-(S-RBD) and anti-nucleocapsid immunoglobulin] at three time points. Antibody level trajectories and frequency of breakthrough infections were evaluated by tumor type and timing of treatment relative to vaccination. IgG-(S-RBD) at peak response (median = 42 days after dose 2) was higher (P = 0.002) and remained higher after 4 to 6 months (P = 0.003) in patients receiving mRNA-1273 compared with BNT162b2. Patients with solid tumors attained higher peak levels (P = 0.001) and sustained levels after 4 to 6 months (P < 0.001) compared with those with hematologic malignancies. B-cell targeted treatment reduced peak (P = 0.001) and sustained antibody responses (P = 0.003). Solid tumor patients receiving immune checkpoint inhibitors before vaccination had lower sustained antibody levels than those who received treatment after vaccination (P = 0.043). Two (0.69%) vaccinated and one (1.9%) unvaccinated patient had severe COVID-19 illness during follow-up. Our study shows variation in sustained antibody responses across cancer populations receiving various therapeutic modalities, with important implications for vaccine booster timing and patient selection. SIGNIFICANCE: Long-term studies of immunogenicity of SARS-CoV-2 vaccines in patients with cancer are needed to inform evidence-based guidelines for booster vaccinations and to tailor sequence and timing of vaccinations to elicit improved humoral responses.
Collapse
Affiliation(s)
- Jane C Figueiredo
- Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
| | - Noah M Merin
- Division of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Omid Hamid
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California
| | - So Yung Choi
- Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California
| | - Tucker Lemos
- Division of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Wendy Cozen
- Division of Hematology/Oncology, Department of Medicine, Department of Pathology, School of Medicine, University of California Irvine, Orange, California
| | - Nathalie Nguyen
- Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California
| | - Laurel J Finster
- Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California
| | - Joslyn Foley
- Division of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Justin Darrah
- Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California
| | - Jun Gong
- Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California
| | - Ronald Paquette
- Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California
| | - Alain C Mita
- Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California
| | - Robert Vescio
- Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California
| | - Inderjit Mehmi
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California
| | - Reva Basho
- Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California
| | - Warren G Tourtellotte
- Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California
| | - Carissa A Huynh
- Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California
| | - Gil Y Melmed
- F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California
| | - Jonathan Braun
- F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California
| | - Dermot P B McGovern
- F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California
| | - Emebet Mengesha
- F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California
| | - Greg Botwin
- F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California
| | | | | | | | - Sandy Joung
- Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Jennifer Van Eyk
- Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California
- Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Joseph E Ebinger
- Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Susan Cheng
- Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Kimia Sobhani
- Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California
| | - Karen L Reckamp
- Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
| | - Akil Merchant
- Division of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
| |
Collapse
|
18
|
Marek-Iannucci S, Ozdemir AB, Moreira D, Gomez AC, Lane M, Porritt RA, Lee Y, Shimada K, Abe M, Stotland A, Zemmour D, Parker S, Sanchez-Lopez E, Van Eyk J, Gottlieb RA, Fishbein M, Karin M, Crother TR, Noval Rivas M, Arditi M. Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis. JCI Insight 2021; 6:e151981. [PMID: 34403365 PMCID: PMC8492304 DOI: 10.1172/jci.insight.151981] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Accepted: 08/11/2021] [Indexed: 01/18/2023] Open
Abstract
Kawasaki disease (KD) is the leading cause of acquired heart disease among children. Murine and human data suggest that the NLRP3-IL-1β pathway is the main driver of KD pathophysiology. NLRP3 can be activated during defective autophagy/mitophagy. We used the Lactobacillus casei cell wall extract (LCWE) murine model of KD vasculitis, to examine the role of autophagy/mitophagy on cardiovascular lesion development. LCWE-injected mice had impaired autophagy/mitophagy and increased levels of ROS in cardiovascular lesions, together with increased systemic 8-OHdG release. Enhanced autophagic flux significantly reduced cardiovascular lesions in LCWE-injected mice, whereas autophagy blockade increased inflammation. Vascular smooth muscle cell specific deletion of Atg16l1 and global Parkin-/- significantly increased disease formation, supporting the importance of autophagy/mitophagy in this model. Ogg1-/- mice had significantly increased lesions with increased NLRP3 activity, whereas treatment with MitoQ, reduced vascular tissue inflammation, ROS production and systemic 8-OHdG release. Treatment with MN58b or Metformin (increasing AMPK and reducing ROS), resulted in decreased disease formation. Our results demonstrate that impaired autophagy/mitophagy and ROS-dependent damage exacerbate the development of murine KD vasculitis. This pathway can be efficiently targeted to reduce disease severity. These findings enhance our understanding of KD pathogenesis and identify novel therapeutic avenues for KD treatment.
Collapse
Affiliation(s)
- Stefanie Marek-Iannucci
- Graduate School of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - A Beyza Ozdemir
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Debbie Moreira
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Angela C Gomez
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Malcolm Lane
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Rebecca A Porritt
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Youngho Lee
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Kenichi Shimada
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Masanori Abe
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Aleksandr Stotland
- Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - David Zemmour
- Department of Pathology, Harvard Medical School and Brigham and Women's Hospital, Boston, United States of America
| | - Sarah Parker
- Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | | | - Jennifer Van Eyk
- Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Roberta A Gottlieb
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Michael Fishbein
- Department of Pathology, UCLA, Los Angeles, United States of America
| | - Michael Karin
- Department of Pathology, UCSD, San Diego, United States of America
| | - Timothy R Crother
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Magali Noval Rivas
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - Moshe Arditi
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, United States of America
| |
Collapse
|
19
|
Porritt RA, Paschold L, Rivas MN, Cheng MH, Yonker LM, Chandnani H, Lopez M, Simnica D, Schultheiß C, Santiskulvong C, Van Eyk J, McCormick JK, Fasano A, Bahar I, Binder M, Arditi M. HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. J Clin Invest 2021; 131:146614. [PMID: 33705359 PMCID: PMC8121516 DOI: 10.1172/jci146614] [Citation(s) in RCA: 110] [Impact Index Per Article: 36.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Accepted: 03/04/2021] [Indexed: 12/12/2022] Open
Abstract
Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory syndrome associated with SARS-CoV-2 infection, shares clinical features with toxic shock syndrome, which is triggered by bacterial superantigens. Superantigen specificity for different Vβ chains results in Vβ skewing, whereby T cells with specific Vβ chains and diverse antigen specificity are overrepresented in the T cell receptor (TCR) repertoire. Here, we characterized the TCR repertoire of MIS-C patients and found a profound expansion of TCRβ variable gene 11-2 (TRBV11-2), with up to 24% of clonal T cell space occupied by TRBV11-2 T cells, which correlated with MIS-C severity and serum cytokine levels. Analysis of TRBJ gene usage and complementarity-determining region 3 (CDR3) length distribution of MIS-C expanded TRBV11-2 clones revealed extensive junctional diversity. Patients with TRBV11-2 expansion shared HLA class I alleles A02, B35, and C04, indicating what we believe is a novel mechanism for CDR3-independent T cell expansion. In silico modeling indicated that polyacidic residues in the Vβ chain encoded by TRBV11-2 (Vβ21.3) strongly interact with the superantigen-like motif of SARS-CoV-2 spike glycoprotein, suggesting that unprocessed SARS-CoV-2 spike may directly mediate TRBV11-2 expansion. Overall, our data indicate that a CDR3-independent interaction between SARS-CoV-2 spike and TCR leads to T cell expansion and possibly activation, which may account for the clinical presentation of MIS-C.
Collapse
Affiliation(s)
- Rebecca A. Porritt
- Departments of Pediatrics, Division of Infectious Diseases and Immunology, Infectious and Immunologic Diseases Research Center (IIDRC) and Department of Biomedical Sciences and
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Lisa Paschold
- Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
| | - Magali Noval Rivas
- Departments of Pediatrics, Division of Infectious Diseases and Immunology, Infectious and Immunologic Diseases Research Center (IIDRC) and Department of Biomedical Sciences and
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Mary Hongying Cheng
- Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Lael M. Yonker
- Mucosal Immunology and Biology Research Center and Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Harsha Chandnani
- Department of Pediatrics, Loma Linda University Hospital, Loma Linda, California, USA
| | - Merrick Lopez
- Department of Pediatrics, Loma Linda University Hospital, Loma Linda, California, USA
| | - Donjete Simnica
- Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
| | - Christoph Schultheiß
- Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
| | | | - Jennifer Van Eyk
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - John K. McCormick
- Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada
| | - Alessio Fasano
- Mucosal Immunology and Biology Research Center and Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Ivet Bahar
- Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Mascha Binder
- Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
| | - Moshe Arditi
- Departments of Pediatrics, Division of Infectious Diseases and Immunology, Infectious and Immunologic Diseases Research Center (IIDRC) and Department of Biomedical Sciences and
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| |
Collapse
|
20
|
Tjoe B, Gresham G, Joung S, Arnold C, Dhawan S, Fuller G, Speier W, Mastali M, Mouapi K, van den Broek I, Wei J, Spiegel B, Van Eyk J, Merz CNB, Shufelt C. PATIENT REPORTED FUNCTIONAL STATUS AS A PREDICTOR FOR N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT-PROBNP) AND CARDIOVASCULAR HOSPITALIZATIONS IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE: A REPORT FROM THE PREDICTION, RISK, AND EVALUATION OF MAJOR ADVERSE CARDIAC EVENTS (PRE-MACE) STUDY. J Am Coll Cardiol 2021. [DOI: 10.1016/s0735-1097(21)01532-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Gresham G, Tjoe B, Joung S, Arnold C, Dhawan S, Fuller G, Speier W, Mastali M, Mouapi K, Van Den Broek I, Wei J, Spiegel B, Van Eyk J, Merz CNB, Shufelt C. LONGITUDINAL TRAJECTORIES OF REMOTELY-MONITORED ACTIVITY DATA IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE (SIHD): A REPORT FROM THE PREDICTION, RISK, AND EVALUATION OF MAJOR ADVERSE CARDIAC EVENTS (PRE-MACE) STUDY. J Am Coll Cardiol 2021. [DOI: 10.1016/s0735-1097(21)04600-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
Tjoe B, Gresham G, Joung S, Arnold C, Dhawan S, Fuller G, Speier W, Mastali M, Mouapi K, van den Broek I, Wei J, Spiegel B, Van Eyk J, Merz CNB, Shufelt C. REMOTE PATIENT MONITORING FOR PREDICTING MAJOR ADVERSE CARDIAC EVENTS (MACE) AND CARDIOVASCULAR HOSPITALIZATIONS IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE (SIHD): A REPORT FROM THE PREDICTION, RISK, AND EVALUATION OF MAJOR ADVERSE CARDIAC EVENTS (PRE-MACE) STUDY. J Am Coll Cardiol 2021. [DOI: 10.1016/s0735-1097(21)04605-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Lynch D, Howze A, Januzzi JL, Van Eyk J, Hui D. IDENTIFICATION OF PLASMA PROTEOMIC BIOMARKERS OF OBSTRUCTIVE CORONARY DISEASE AMONG PATIENTS WITH DIABETES. J Am Coll Cardiol 2021. [DOI: 10.1016/s0735-1097(21)01536-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
24
|
Porritt RA, Paschold L, Noval Rivas M, Hongying Cheng M, Yonker LM, Chandnani H, Lopez M, Simnica D, Schultheiß C, Santiskulvong C, Van Eyk J, Fasano A, Bahar I, Binder M, Arditi M. Identification of a unique TCR repertoire, consistent with a superantigen selection process in Children with Multi-system Inflammatory Syndrome. bioRxiv 2020:2020.11.09.372169. [PMID: 33200133 PMCID: PMC7668738 DOI: 10.1101/2020.11.09.372169] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Multisystem Inflammatory Syndrome in Children (MIS-C), a hyperinflammatory syndrome associated with SARS-CoV-2 infection, shares many clinical features with toxic shock syndrome, which is triggered by bacterial superantigens. The superantigen specificity for binding different Vβ-chains results in Vβ-skewing, whereby T cells with specific Vβ-chains and diverse antigen specificity are overrepresented in the TCR repertoire. Here, we characterized the TCR repertoire of MIS-C patients and found a profound expansion of TCR Βeta Variable gene (TRBV)11-2. Furthermore, TRBV11-2 skewing was remarkably correlated with MIS-C severity and serum cytokine levels. Further analysis of TRBJ gene usage and CDR3 length distribution of MIS-C expanding TRBV11-2 clones revealed extensive junctional diversity, indicating a superantigen-mediated selection process for TRBV expansion. In silico modelling indicates that polyacidic residues in TCR Vβ11-2 engage in strong interactions with the superantigen-like motif of SARS-CoV-2 spike glycoprotein. Overall, our data indicate that the immune response in MIS-C is consistent with superantigenic activation.
Collapse
Affiliation(s)
- Rebecca A Porritt
- Departments of Pediatrics, Division of Infectious Diseases and Immunology, Infectious and Immunologic Diseases Research Center (IIDRC) and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Lisa Paschold
- Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany
| | - Magali Noval Rivas
- Departments of Pediatrics, Division of Infectious Diseases and Immunology, Infectious and Immunologic Diseases Research Center (IIDRC) and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Mary Hongying Cheng
- Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Lael M Yonker
- Mucosal Immunology and Biology Research Center and Department of Pediatrics, Boston, Massachusetts General Hospital, MA, USA
| | - Harsha Chandnani
- Department of Pediatrics, Loma Linda University Hospital, CA, USA
| | - Merrick Lopez
- Department of Pediatrics, Loma Linda University Hospital, CA, USA
| | - Donjete Simnica
- Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany
| | - Christoph Schultheiß
- Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany
| | | | - Jennifer Van Eyk
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Alessio Fasano
- Mucosal Immunology and Biology Research Center and Department of Pediatrics, Boston, Massachusetts General Hospital, MA, USA
| | - Ivet Bahar
- Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Mascha Binder
- Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany
| | - Moshe Arditi
- Departments of Pediatrics, Division of Infectious Diseases and Immunology, Infectious and Immunologic Diseases Research Center (IIDRC) and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| |
Collapse
|
25
|
AlBadri A, Wei J, Quesada O, Mehta PK, Xiao Y, Ko YA, Anderson RD, Petersen J, Azarbal B, Samuels B, Henry TD, Cook-Wiens G, Handberg EM, Van Eyk J, Pepine CJ, Bairey Merz CN. Coronary Vascular Function and Cardiomyocyte Injury: A Report From the WISE-CVD. Arterioscler Thromb Vasc Biol 2020; 40:3015-3021. [PMID: 33028098 DOI: 10.1161/atvbaha.120.314260] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Women with symptoms or signs of myocardial ischemia but no obstructive coronary artery disease (INOCA) often have coronary vascular dysfunction and elevated risk for adverse cardiovascular events. We hypothesized that u-hscTnI (ultra-high-sensitivity cardiac troponin I), a sensitive indicator of ischemic cardiomyocyte injury, is associated with coronary vascular dysfunction in women with INOCA. Approach and Results: Women (N=263) with INOCA enrolled in the WISE-CVD study (Women's Ischemic Syndrome Evaluation-Coronary Vascular Dysfunction) underwent invasive coronary vascular function testing and u-hscTnI measurements (Simoa HD-1 Analyzer; Quanterix Corporation, Lexington, MA). Logistic regression models, adjusted for traditional cardiovascular risk factors were used to evaluate associations between u-hscTnI and coronary vascular function. Women with coronary vascular dysfunction (microvascular constriction and limited coronary epicardial dilation) had higher plasma u-hscTnI levels (both P=0.001). u-hscTnI levels were associated with microvascular constriction (odds ratio, 1.38 per doubling of u-hscTnI [95% CI, 1.03-1.84]; P=0.033) and limited coronary epicardial dilation (odds ratio, 1.37 per doubling of u-hscTnI [95% CI, 1.04-1.81]; P=0.026). u-hscTnI levels were not associated with microvascular dilation or coronary epicardial constriction. CONCLUSIONS Our findings indicate that higher u-hscTnI is associated with coronary vascular dysfunction in women with INOCA. This suggests that ischemic cardiomyocyte injury in the setting of coronary vascular dysfunction has the potential to contribute to adverse cardiovascular outcomes observed in these women. Additional studies are needed to confirm and investigate mechanisms underlying these findings in INOCA. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00832702.
Collapse
Affiliation(s)
- Ahmed AlBadri
- Emory Clinical Cardiovascular Research Institute, Department of Medicine, Emory University School of Medicine, Atlanta, GA (A.A., P.K.M., Y.X., Y.-A.K.)
| | - Janet Wei
- Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA (J.W., O.Q., B.A., B.S., T.D.H., J.V.E., C.N.B.M.)
| | - Odayme Quesada
- Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA (J.W., O.Q., B.A., B.S., T.D.H., J.V.E., C.N.B.M.)
| | - Puja K Mehta
- Emory Clinical Cardiovascular Research Institute, Department of Medicine, Emory University School of Medicine, Atlanta, GA (A.A., P.K.M., Y.X., Y.-A.K.)
| | - Yi Xiao
- Emory Clinical Cardiovascular Research Institute, Department of Medicine, Emory University School of Medicine, Atlanta, GA (A.A., P.K.M., Y.X., Y.-A.K.)
| | - Yi-An Ko
- Emory Clinical Cardiovascular Research Institute, Department of Medicine, Emory University School of Medicine, Atlanta, GA (A.A., P.K.M., Y.X., Y.-A.K.)
| | - R David Anderson
- Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (R.D.A., J.P., E.M.H., C.J.P.)
| | - John Petersen
- Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (R.D.A., J.P., E.M.H., C.J.P.)
| | - Babak Azarbal
- Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA (J.W., O.Q., B.A., B.S., T.D.H., J.V.E., C.N.B.M.)
| | - Bruce Samuels
- Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA (J.W., O.Q., B.A., B.S., T.D.H., J.V.E., C.N.B.M.)
| | - Timothy D Henry
- Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA (J.W., O.Q., B.A., B.S., T.D.H., J.V.E., C.N.B.M.)
| | - Galen Cook-Wiens
- Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, CA (G.C.-W.)
| | - Eileen M Handberg
- Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (R.D.A., J.P., E.M.H., C.J.P.)
| | - Jennifer Van Eyk
- Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA (J.W., O.Q., B.A., B.S., T.D.H., J.V.E., C.N.B.M.)
| | - Carl J Pepine
- Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville (R.D.A., J.P., E.M.H., C.J.P.)
| | - C Noel Bairey Merz
- Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA (J.W., O.Q., B.A., B.S., T.D.H., J.V.E., C.N.B.M.)
| |
Collapse
|
26
|
Vatine GD, Barrile R, Workman MJ, Sances S, Barriga BK, Rahnama M, Barthakur S, Kasendra M, Lucchesi C, Kerns J, Wen N, Spivia WR, Chen Z, Van Eyk J, Svendsen CN. Human iPSC-Derived Blood-Brain Barrier Chips Enable Disease Modeling and Personalized Medicine Applications. Cell Stem Cell 2020; 24:995-1005.e6. [PMID: 31173718 DOI: 10.1016/j.stem.2019.05.011] [Citation(s) in RCA: 314] [Impact Index Per Article: 78.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2018] [Revised: 02/24/2019] [Accepted: 05/13/2019] [Indexed: 12/22/2022]
Abstract
The blood-brain barrier (BBB) tightly regulates the entry of solutes from blood into the brain and is disrupted in several neurological diseases. Using Organ-Chip technology, we created an entirely human BBB-Chip with induced pluripotent stem cell (iPSC)-derived brain microvascular endothelial-like cells (iBMECs), astrocytes, and neurons. The iBMECs formed a tight monolayer that expressed markers specific to brain vasculature. The BBB-Chip exhibited physiologically relevant transendothelial electrical resistance and accurately predicted blood-to-brain permeability of pharmacologics. Upon perfusing the vascular lumen with whole blood, the microengineered capillary wall protected neural cells from plasma-induced toxicity. Patient-derived iPSCs from individuals with neurological diseases predicted disease-specific lack of transporters and disruption of barrier integrity. By combining Organ-Chip technology and human iPSC-derived tissue, we have created a neurovascular unit that recapitulates complex BBB functions, provides a platform for modeling inheritable neurological disorders, and advances drug screening, as well as personalized medicine.
Collapse
Affiliation(s)
- Gad D Vatine
- The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; The Department of Physiology and Cell Biology and the Regenerative Medicine and Stem Cell (RMSC) Research Center, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel.
| | - Riccardo Barrile
- The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Emulate, Inc., 27 Drydock Avenue, Boston, MA 02210, USA
| | - Michael J Workman
- The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Samuel Sances
- The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Bianca K Barriga
- The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Matthew Rahnama
- The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | | | | | | | - Jordan Kerns
- Emulate, Inc., 27 Drydock Avenue, Boston, MA 02210, USA
| | - Norman Wen
- Emulate, Inc., 27 Drydock Avenue, Boston, MA 02210, USA
| | - Weston R Spivia
- Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Zhaohui Chen
- Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Jennifer Van Eyk
- Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Clive N Svendsen
- The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
| |
Collapse
|
27
|
Shufelt C, Cheng S, Fuller G, Joung S, Mastali M, Mouapi K, Fu Q, Lopez M, Spiegel B, Van Eyk J, Merz CNB. RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES AND CARDIAC BIOMARKERS: THE PREDICTION, RISK, AND EVALUATION OF MAJOR ADVERSE CARDIAC EVENTS (PRE-MACE) STUDY BASELINE RESULTS. J Am Coll Cardiol 2019. [DOI: 10.1016/s0735-1097(19)32437-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Kothari P, Srivastava V, Aggarwal V, Tchernyshyov I, Van Eyk J, Ha T, Robinson DN. Mapping the Biochemical Interactions of the Mechanoresponsive Contractility Controller. Biophys J 2019. [DOI: 10.1016/j.bpj.2018.11.669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
29
|
Papadaki M, Holewisnki R, Previs S, Martin T, Stachowski M, Li A, Blair C, Campbell K, Christine M, Van Eyk J, Aubert V, Warshaw D, Kirk J. Diabetes with Heart Failure Increases Methylglyoxal Modifications in the Sarcomere Which Inhibit Function. Biophys J 2019. [DOI: 10.1016/j.bpj.2018.11.645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
30
|
Berg AH, Van Eyk J. Which Methods for Determining Glomerular Filtration Rate Most Strongly Associate with Risk of Progression of Kidney Disease? Clin Chem 2019; 65:361-362. [PMID: 30647125 DOI: 10.1373/clinchem.2018.300731] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2018] [Accepted: 12/27/2018] [Indexed: 11/06/2022]
Affiliation(s)
- Anders H Berg
- Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA;
| | | |
Collapse
|
31
|
Anger J, Spivia W, van den Broek I, Crear D, Ackerman AL, Eilber K, Freeman M, Kim J, Fu Q, Van Eyk J, Chronic Pelvic Pain (MAPP) Network MDATTSO. MP38-15 DIFFERENTIAL PROTEIN EXPRESSION IN PATIENTS WITH UCPPS: A MAPP STUDY. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.1242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
32
|
Parker SJ, Stotland A, Orosco A, Wilson NPD, MacFarlane E, Madrid K, Gottlieb R, Dietz HC, Van Eyk J. Proteomics Reveals Context‐Dependent Activation of Rictor Signaling by TGFβ in Vascular Smooth Muscle Cells. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.586.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | - Amanda Orosco
- Heart InstituteCedars‐Sinai Medical CenterLos AngelesCA
| | | | - Elena MacFarlane
- Institute for Genetic MedicineJohns Hopkins UniversityBaltimoreMD
| | - Kyle Madrid
- Biological SciencesCedars‐Sinai Medical CenterLos AngelesCA
| | | | - Harry C. Dietz
- Institute for Genetic MedicineJohns Hopkins UniversityBaltimoreMD
| | | |
Collapse
|
33
|
Soetkamp D, Raedschelders K, Mastali M, Sobhani K, Bairey Merz CN, Van Eyk J. The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform. Expert Rev Proteomics 2017; 14:973-986. [PMID: 28984473 DOI: 10.1080/14789450.2017.1387054] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
INTRODUCTION The troponin complex consists of three proteins that fundamentally couple excitation with contraction. Circulating cardiac-specific Troponin I (cTnI) serves as diagnostic biomarker tools for risk stratification of acute coronary syndromes and acute myocardial infarction (MI). Within the heart, cTnI oscillates between inactive and active conformations to either block or disinhibit actinomyosin formation. This molecular mechanism is fine-tuned through extensive protein modifications whose profiles are maladaptively altered with co-morbidities including hypertrophic cardiomyopathy, diabetes, and heart failure. Technological advances in analytical platforms over the last decade enable routine baseline cTnI analysis in patients without cardiovascular complications, and hold potential to expand cTnI readouts that include modified cTnI proteoforms. Areas covered: This review covers the current state, advances, and prospects of analytical platforms that now enable routine baseline cTnI analysis in patients. In parallel, improved mass spectrometry instrumentation and workflows already reveal an array of modified cTnI proteoforms with promising diagnostic implications. Expert commentary: New analytical capabilities provide clinicians and researchers with an opportunity to address important questions surrounding circulating cTnI in the improved diagnosis of specific patient cohorts. These techniques also hold considerable promise for new predictive and prescriptive applications for individualized profiling and improve patient care.
Collapse
Affiliation(s)
- Daniel Soetkamp
- a Heart Institute , Cedars-Sinai Medical Center , Los Angeles , CA , USA
| | - Koen Raedschelders
- a Heart Institute , Cedars-Sinai Medical Center , Los Angeles , CA , USA
| | - Mitra Mastali
- a Heart Institute , Cedars-Sinai Medical Center , Los Angeles , CA , USA
| | - Kimia Sobhani
- b Pathology and Laboratory Medicine , Cedars-Sinai Medical Center , Los Angeles , CA , USA
| | - C Noel Bairey Merz
- c Women's Heart Center , Cedars-Sinai Medical Center , Los Angeles , CA , USA
| | - Jennifer Van Eyk
- a Heart Institute , Cedars-Sinai Medical Center , Los Angeles , CA , USA
| |
Collapse
|
34
|
Vadakke Madathil S, Ranjan A, Yoon J, Tripodi J, Raedschelders K, Parker S, Najfeld V, Van Eyk J, Chaudhry H. Abstract 198: Multipotent Placenta-derived Cdx2 Cells Possess in vitro and in vivo Cardiomyogenic Potential. Circ Res 2017. [DOI: 10.1161/res.121.suppl_1.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Stem cell-based therapies for cardiac regeneration are of crucial importance and an ideal cell-type is yet to be established. We previously reported that fetal cells from placenta “home” to injured maternal heart and approximately 40% (40/100) of the migrating cells expressed homeodomain protein Cdx2. This interesting observation led us to hypothesize that placental Cdx2 could be a novel cell target for cardiac differentiation. To understand this phenomenon, we employed a cre-lox strategy that labeled Cdx2 cells in placenta with e-GFP and induced myocardial infarction (MI) in pregnant mice at mid-gestation. The maternal heart was analyzed 4 weeks post-MI for the presence of Cdx2-eGFP-derived cardiomyocytes. Additionally, Cdx2 cells were isolated from late-gestation placenta and assayed for cardiac differentiation
in vitro
followed by live cell imaging. Phenotypic and whole-cell proteomic analysis, clonal and vascular lineage differentiation and immune profiling were carried out subsequently. We observed that Cdx2 cells migrated to injured maternal hearts and differentiated into cardiomyocytes highlighting the functional significance of fetal-maternal stem cell transfer. Additionally, isolated Cdx2 cells from the late placenta differentiated into spontaneously beating cardiomyocytes and expressed structural proteins cardiac troponin T(cTnT), α-sarcomeric actinin and gap junction protein Cx43. These cells underwent clonal expansion and differentiated into endothelial and smooth muscle lineages in culture indicative of their multipotent nature. Low expression of MHC molecules and other components of the immune-response, infer that these cells possess the ability to evade host immune surveillance. Proteomic analysis demonstrated that 145 proteins were uniquely identified in the Cdx2 cells compared to embryonic stem cells. These protein networks reflected an increased activation of functions involving migration, fertility, homing, and chemotaxis. Our study is the first to demonstrate that Cdx2 may play a role in cardiac differentiation and delineate multipotent cells in placenta with an inherent “homing” ability. These findings point to a potential role for Cdx2 cells in cardiac regenerative therapies using allogeneic cells.
Collapse
Affiliation(s)
| | | | - Jesse Yoon
- Icahn Sch of Medicine at Mount Sinai, New York, NY
| | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
Abstract
Background: High mobility group box 1 (HMGB1) is a versatile protein with dual roles. Within the cell, this highly conserved chromosomal protein functions as a DNA chaperone. Outside of the cell, it functions as the prototypical damage-associated molecular pattern. There is significant evidence that HMGB1 dysfunction contributes to cancer development, particularly in mesothelioma, where its role in carcinogenesis is better defined.
Goal: To develop a mass spectrometry based immune-multiple reaction monitoring (iMRM) assay to quantify HMGB1 and its disease-associated post-translationally modified forms.
Methods: Mesothelioma cell lines (Ren, Phi and PP-Mill) known to secrete HMGB1 were used. Concentrated cell line supernatants, anti-HMGB1 antibody-loaded magnetic beads were incubated overnight. Beads were extensively washed and the HMGB1 released from the beads was enzymatically digested prior to targeted MRM mass spectrometry. Known quantity of N15 labeled synthetic peptides were spiked in to be used as internal standards to assess the total protein concentrations as well as the acetylated modified peptides that encompass the Lys residue. To ensure tight reproducibility during sample processing, we developed an automated workflow from enrichment to digestion with % coefficient of variance of less than 20%.
Results: Two multiplex MRM assays were developed for HMGB1: 1) total HMGB1 protein assay based on trypsin digested peptides and 2) Acetylated HMGB1 assay based on Endoproteinase GluC (Staphylococcus aureus Protease V8) digestion to obtain the peptides containing hyper-acetylated Lysine residues, which are not located within a suitable tryptic peptide. Four significant milestones were accomplished. i) We optimized the HMGB1 liquid chromatography and mass spectrometry performance through the utilization of signature synthesized peptides representing the common amino acid sequence and potential acetylated regions. The calibration curves for both peptides based on the ratio of light and heavy isotopic labeled internal standards were achieved. LLOD and LLOQ and the inter and intra-day variability of the iMRM assay have been achieved. ii) A robust immuno-capture protocol was established. The final protocol included isolation of HMGB1 using a capture antibody followed by protein release, denaturation, reduction, alkylation and digestion. To date, we have optimized the conditions for HMGB1 attachment to antibody, antibody coupling to magnetic beads, the wash and elution steps. iii) The protocol was applied to quantify HMGB1 in mesothelioma cell lines. HMGB1 was measured in cytoplasm, nucleus and supernatant from the cell lines. iv) Finally, the assay was adapted to work on human plasma samples.
Conclusion: We successfully developed the iMRM workflow for quantification of total HMGB1 and acetylated HMGB1 based on the measurement of the target signature peptides in HMGB1.
Citation Format: Dawn Zhaohui Chen, Weston R. Spivia, Yang Gao, Jennifer Van Eyk, Shreya Kanodia. A novel MRM-based mass spectrometry assay to quantify HMGB1 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2216. doi:10.1158/1538-7445.AM2017-2216
Collapse
Affiliation(s)
| | | | - Yang Gao
- Cedars-Sinai Medical Center, Los Angeles, CA
| | | | | |
Collapse
|
36
|
Hixson JE, Jun G, Shimmin LC, Wang Y, Yu G, Mao C, Warren AS, Howard TD, Heide RSV, Van Eyk J, Wang Y, Herrington DM. Whole Exome Sequencing to Identify Genetic Variants Associated with Raised Atherosclerotic Lesions in Young Persons. Sci Rep 2017. [PMID: 28642624 PMCID: PMC5481334 DOI: 10.1038/s41598-017-04433-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
We investigated the influence of genetic variants on atherosclerosis using whole exome sequencing in cases and controls from the autopsy study “Pathobiological Determinants of Atherosclerosis in Youth (PDAY)”. We identified a PDAY case group with the highest total amounts of raised lesions (n = 359) for comparisons with a control group with no detectable raised lesions (n = 626). In addition to the standard exome capture, we included genome-wide proximal promoter regions that contain sequences that regulate gene expression. Our statistical analyses included single variant analysis for common variants (MAF > 0.01) and rare variant analysis for low frequency and rare variants (MAF < 0.05). In addition, we investigated known CAD genes previously identified by meta-analysis of GWAS studies. We did not identify individual common variants that reached exome-wide significance using single variant analysis. In analysis limited to 60 CAD genes, we detected strong associations with COL4A2/COL4A1 that also previously showed associations with myocardial infarction and arterial stiffness, as well as coronary artery calcification. Likewise, rare variant analysis did not identify genes that reached exome-wide significance. Among the 60 CAD genes, the strongest association was with NBEAL1 that was also identified in gene-based analysis of whole exome sequencing for early onset myocardial infarction.
Collapse
Affiliation(s)
- James E Hixson
- Human Genetics Center, UTHealth School of Public Health, Houston, TX, 77030, USA.
| | - Goo Jun
- Human Genetics Center, UTHealth School of Public Health, Houston, TX, 77030, USA
| | - Lawrence C Shimmin
- Human Genetics Center, UTHealth School of Public Health, Houston, TX, 77030, USA
| | - Yizhi Wang
- Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA, 22203, USA
| | - Guoqiang Yu
- Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA, 22203, USA
| | - Chunhong Mao
- Biocomplexity Institute of Virginia Tech, Virginia Tech, Blacksburg, VA, 24061, USA
| | - Andrew S Warren
- Biocomplexity Institute of Virginia Tech, Virginia Tech, Blacksburg, VA, 24061, USA
| | - Timothy D Howard
- Center for Genomics & Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| | - Richard S Vander Heide
- Department of Pathology, Louisiana State University Health Science Center, New Orleans, LA, 70112, USA
| | - Jennifer Van Eyk
- Advanced Clinical BioSystems Research Institute, Heart Institute and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA
| | - Yue Wang
- Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA, 22203, USA
| | - David M Herrington
- Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
| |
Collapse
|
37
|
Vatine GD, Al-Ahmad A, Barriga BK, Svendsen S, Salim A, Garcia L, Garcia VJ, Ho R, Yucer N, Qian T, Lim RG, Wu J, Thompson LM, Spivia WR, Chen Z, Van Eyk J, Palecek SP, Refetoff S, Shusta EV, Svendsen CN. Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier. Cell Stem Cell 2017; 20:831-843.e5. [PMID: 28526555 PMCID: PMC6659720 DOI: 10.1016/j.stem.2017.04.002] [Citation(s) in RCA: 153] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 04/29/2016] [Accepted: 04/07/2017] [Indexed: 12/27/2022]
Abstract
Inactivating mutations in the thyroid hormone (TH) transporter Monocarboxylate transporter 8 (MCT8) cause severe psychomotor retardation in children. Animal models do not reflect the biology of the human disease. Using patient-specific induced pluripotent stem cells (iPSCs), we generated MCT8-deficient neural cells that showed normal TH-dependent neuronal properties and maturation. However, the blood-brain barrier (BBB) controls TH entry into the brain, and reduced TH availability to neural cells could instead underlie the diseased phenotype. To test potential BBB involvement, we generated an iPSC-based BBB model of MCT8 deficiency, and we found that MCT8 was necessary for polarized influx of the active form of TH across the BBB. We also found that a candidate drug did not appreciably cross the mutant BBB. Our results therefore clarify the underlying physiological basis of this disorder, and they suggest that circumventing the diseased BBB to deliver active TH to the brain could be a viable therapeutic strategy.
Collapse
Affiliation(s)
- Gad D Vatine
- The Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Abraham Al-Ahmad
- Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA; Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
| | - Bianca K Barriga
- The Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Soshana Svendsen
- The Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Ariel Salim
- The Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Leslie Garcia
- The Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Veronica J Garcia
- The Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Ritchie Ho
- The Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Nur Yucer
- The Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Tongcheng Qian
- Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Ryan G Lim
- Department of Biological Chemistry, University of California, Irvine (UCI), Irvine, CA 92697, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine (UCI), Irvine, CA 92697, USA
| | - Jie Wu
- Department of Biological Chemistry, University of California, Irvine (UCI), Irvine, CA 92697, USA
| | - Leslie M Thompson
- Department of Biological Chemistry, University of California, Irvine (UCI), Irvine, CA 92697, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine (UCI), Irvine, CA 92697, USA; Department of Neurobiology and Behavior, University of California, Irvine (UCI), Irvine, CA 92697, USA; Department of Psychiatry and Human Behavior, University of California, Irvine (UCI), Irvine, CA 92697, USA; Sue and Bill Gross Stem Cell Center, University of California, Irvine (UCI), Irvine, CA 92697, USA
| | - Weston R Spivia
- Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Zhaohui Chen
- Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Jennifer Van Eyk
- Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Sean P Palecek
- Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Samuel Refetoff
- Department of Medicine, Pediatrics and Committee on Genetics, The University of Chicago, Chicago, IL 60637, USA
| | - Eric V Shusta
- Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA.
| | - Clive N Svendsen
- The Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
| |
Collapse
|
38
|
Alonso C, Fernández-Ramos D, Varela-Rey M, Martínez-Arranz I, Navasa N, Van Liempd SM, Lavin JL, Mayo R, Ilisso CP, de Juan VG, Iruarrizaga-Lejarreta M, delaCruz-Villar L, Mincholé I, Robinson A, Crespo J, Martín-Duce A, Romero-Gomez M, Sann H, Platon J, Van Eyk J, Aspichueta P, Noureddin M, Falcón-Pérez JM, Anguita J, Aransay AM, Martínez-Chantar ML, Lu SC, Mato JM. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology 2017; 152:1449-1461.e7. [PMID: 28132890 PMCID: PMC5406239 DOI: 10.1053/j.gastro.2017.01.015] [Citation(s) in RCA: 180] [Impact Index Per Article: 25.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Revised: 12/21/2016] [Accepted: 01/09/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND & AIMS Nonalcoholic fatty liver disease (NAFLD) is a consequence of defects in diverse metabolic pathways that involve hepatic accumulation of triglycerides. Features of these aberrations might determine whether NAFLD progresses to nonalcoholic steatohepatitis (NASH). We investigated whether the diverse defects observed in patients with NAFLD are caused by different NAFLD subtypes with specific serum metabolomic profiles, and whether these can distinguish patients with NASH from patients with simple steatosis. METHODS We collected liver and serum from methionine adenosyltransferase 1a knockout (MAT1A-KO) mice, which have chronically low levels of hepatic S-adenosylmethionine (SAMe) and spontaneously develop steatohepatitis, as well as C57Bl/6 mice (controls); the metabolomes of all samples were determined. We also analyzed serum metabolomes of 535 patients with biopsy-proven NAFLD (353 with simple steatosis and 182 with NASH) and compared them with serum metabolomes of mice. MAT1A-KO mice were also given SAMe (30 mg/kg/day for 8 weeks); liver samples were collected and analyzed histologically for steatohepatitis. RESULTS Livers of MAT1A-KO mice were characterized by high levels of triglycerides, diglycerides, fatty acids, ceramides, and oxidized fatty acids, as well as low levels of SAMe and downstream metabolites. There was a correlation between liver and serum metabolomes. We identified a serum metabolomic signature associated with MAT1A-KO mice that also was present in 49% of the patients; based on this signature, we identified 2 NAFLD subtypes. We identified specific panels of markers that could distinguish patients with NASH from patients with simple steatosis for each subtype of NAFLD. Administration of SAMe reduced features of steatohepatitis in MAT1A-KO mice. CONCLUSIONS In an analysis of serum metabolomes of patients with NAFLD and MAT1A-KO mice with steatohepatitis, we identified 2 major subtypes of NAFLD and markers that differentiate steatosis from NASH in each subtype. These might be used to monitor disease progression and identify therapeutic targets for patients.
Collapse
Affiliation(s)
- Cristina Alonso
- OWL Metabolomics, Parque Tecnológico de Bizkaia, Derio,
Spain
| | | | - Marta Varela-Rey
- CIC bioGUNE, CIBERehd, Parque Tecnológico de Bizkaia, Derio,
Spain
| | | | - Nicolás Navasa
- CIC bioGUNE, CIBERehd, Parque Tecnológico de Bizkaia, Derio,
Spain
| | | | - José L Lavin
- CIC bioGUNE, CIBERehd, Parque Tecnológico de Bizkaia, Derio,
Spain
| | - Rebeca Mayo
- OWL Metabolomics, Parque Tecnológico de Bizkaia, Derio,
Spain
| | | | | | | | | | - Itziar Mincholé
- OWL Metabolomics, Parque Tecnológico de Bizkaia, Derio,
Spain
| | - Aaron Robinson
- Advanced Clinical Biosystems Research Institute, Cedars-Sinai
Medical Center, Los Angeles, CA, USA
| | - Javier Crespo
- Gastroenterology and Hepatology Department. Infection, Immunity and
Digestive Pathology Group. IDIVAL, Instituto de Investigación Valdecilla.
Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Antonio Martín-Duce
- Hospital Universitario Príncipe de Asturias. Faculty of
Medicine and Health Science. Alcalá University, Madrid, Spain
| | - Manuel Romero-Gomez
- Unidad de Enfermedades Digestivas. Hospital Virgen de Valme.
Hospital Universitario Virgen Macarena y Virgen del Rocío. Instituto de
Biomedicina de Sevilla, Universidad de Sevilla, CIBERehd, Seville, Spain
| | - Holger Sann
- Abbott Laboratories GmbH, Freundallee 9A, 30173 Hannover,
Germany
| | - Julian Platon
- Abbott, Hegenheimermattweg 127, 4123 Allschwil, Switzerland
| | - Jennifer Van Eyk
- Advanced Clinical Biosystems Research Institute, Cedars-Sinai
Medical Center, Los Angeles, CA, USA
| | - Patricia Aspichueta
- Department of Physiology, University of the Basque Country,
Biocruces Research Institute, Spain
| | - Mazen Noureddin
- Division of Digestive and Liver Diseases, Cedars-Sinai Medical
Center, Los Angeles, CA, USA
| | | | - Juan Anguita
- CIC bioGUNE, CIBERehd, Parque Tecnológico de Bizkaia, Derio,
Spain
| | - Ana M Aransay
- CIC bioGUNE, CIBERehd, Parque Tecnológico de Bizkaia, Derio,
Spain
| | | | - Shelly C Lu
- Division of Digestive and Liver Diseases, Cedars-Sinai Medical
Center, Los Angeles, CA, USA
| | - José M Mato
- CIC bioGUNE, CIBERehd, Parque Tecnológico de Bizkaia, Derio, Spain.
| |
Collapse
|
39
|
Mao C, Howard TD, Sullivan D, Fu Z, Yu G, Parker SJ, Will R, Vander Heide RS, Wang Y, Hixson J, Van Eyk J, Herrington DM. Bioinformatic Analysis of Coronary Disease Associated SNPs and Genes to Identify Proteins Potentially Involved in the Pathogenesis of Atherosclerosis. ACTA ACUST UNITED AC 2017; 2:1-12. [PMID: 29367937 DOI: 10.14302/issn.2326-0793.jpgr-17-1447] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Factors that contribute to the onset of atherosclerosis may be elucidated by bioinformatic techniques applied to multiple sources of genomic and proteomic data. The results of genome wide association studies, such as the CardioGramPlusC4D study, expression data, such as that available from expression quantitative trait loci (eQTL) databases, along with protein interaction and pathway data available in Ingenuity Pathway Analysis (IPA), constitute a substantial set of data amenable to bioinformatics analysis. This study used bioinformatic analyses of recent genome wide association data to identify a seed set of genes likely associated with atherosclerosis. The set was expanded to include protein interaction candidates to create a network of proteins possibly influencing the onset and progression of atherosclerosis. Local average connectivity (LAC), eigenvector centrality, and betweenness metrics were calculated for the interaction network to identify top gene and protein candidates for a better understanding of the atherosclerotic disease process. The top ranking genes included some known to be involved with cardiovascular disease (APOA1, APOA5, APOB, APOC1, APOC2, APOE, CDKN1A, CXCL12, SCARB1, SMARCA4 and TERT), and others that are less obvious and require further investigation (TP53, MYC, PPARG, YWHAQ, RB1, AR, ESR1, EGFR, UBC and YWHAZ). Collectively these data help define a more focused set of genes that likely play a pivotal role in the pathogenesis of atherosclerosis and are therefore natural targets for novel therapeutic interventions.
Collapse
Affiliation(s)
- Chunhong Mao
- Biocomplexity Institute of Virginia Tech, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA
| | - Timothy D Howard
- Center for Genomics & Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
| | - Dan Sullivan
- Biocomplexity Institute of Virginia Tech, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA
| | - Zongming Fu
- Division of Hematology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Guoqiang Yu
- Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA 22203, USA
| | - Sarah J Parker
- Heart institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048
| | - Rebecca Will
- Biocomplexity Institute of Virginia Tech, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA
| | | | - Yue Wang
- Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA 22203, USA
| | - James Hixson
- Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Jennifer Van Eyk
- Heart institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048
| | - David M Herrington
- Department of Cardiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
| |
Collapse
|
40
|
Peters ME, Rao V, Bechtold KT, Roy D, Sair HI, Leoutsakos JM, Diaz-Arrastia R, Stevens RD, Batty DS, Falk H, Fernandez C, Ofoche U, Vassila A, Hall AJ, Anderson B, Bessman E, Lyketsos CG, Everett AD, Van Eyk J, Korley FK. Head injury serum markers for assessing response to trauma: Design of the HeadSMART study. Brain Inj 2017; 31:370-378. [PMID: 28140672 PMCID: PMC6438171 DOI: 10.1080/02699052.2016.1231344] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2016] [Accepted: 08/29/2016] [Indexed: 01/07/2023]
Abstract
BACKGROUND Accurate diagnosis and risk stratification of traumatic brain injury (TBI) at time of presentation remains a clinical challenge. The Head Injury Serum Markers for Assessing Response to Trauma study (HeadSMART) aims to examine blood-based biomarkers for diagnosing and determining prognosis in TBI. METHODS HeadSMART is a 6-month prospective cohort study comparing emergency department patients evaluated for TBI (exposure group) to (1) emergency department patients evaluated for traumatic injury without head trauma and (2) healthy persons. Study methods and characteristics of the first 300 exposure participants are discussed. RESULTS Of the first 300 participants in the exposure arm, 70% met the American Congress of Rehabilitation Medicine criteria for TBI, with the majority (80.1%) classified as mild TBI. The majority of subjects in the exposure arm had Glasgow Coma Scale scores of 13-15 (98.0%), normal head computed tomography (81.3%) and no prior history of concussion (71.7%). CONCLUSION With systematic phenotyping, HeadSMART will facilitate diagnosis and risk-stratification of the heterogeneous group of individuals currently diagnosed with TBI.
Collapse
Affiliation(s)
| | - Vani Rao
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | | | - Durga Roy
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Haris I. Sair
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | | | | | | | | | - Hayley Falk
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | | | - Uju Ofoche
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | | | - Anna J. Hall
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Braden Anderson
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Edward Bessman
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | | | | | - Jennifer Van Eyk
- The Heart Institute, Department of Medicine, Cedars-Sinai, Los Angeles, CA, USA
| | | |
Collapse
|
41
|
Rucki AA, Foley K, Zhang P, Xiao Q, Kleponis J, Wu AA, Sharma R, Mo G, Liu A, Van Eyk J, Jaffee EM, Zheng L. Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. Cancer Res 2016; 77:41-52. [PMID: 27821486 DOI: 10.1158/0008-5472.can-16-1383] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2016] [Revised: 09/13/2016] [Accepted: 10/11/2016] [Indexed: 12/16/2022]
Abstract
Understanding how stromal signals regulate the development of pancreatic ductal adenocarcinoma (PDAC) may suggest novel therapeutic interventions in this disease. In this study, we assessed the metastatic role of stromal signals suggested to be important in the PDAC microenvironment. Src and IGF-1R phosphorylated the prometastatic molecule Annexin A2 (AnxA2) at Y23 and Y333 in response to stromal signals HGF and IGF-1, respectively, and IGF-1 expression was regulated by the Sonic Hedgehog (Shh) pathway. Both Shh and HGF were heterogeneously expressed in PDAC stroma, and only dual inhibition of these pathways could significantly suppress AnxA2 phosphorylation, PDAC growth, and metastasis. Taken together, our results illuminate tumor-stromal interactions, which drive metastasis, and provide a mechanism-based rationale for a stroma-directed therapy for PDAC. Cancer Res; 77(1); 41-52. ©2016 AACR.
Collapse
Affiliation(s)
- Agnieszka A Rucki
- The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Graduate Program in Cellular and Molecular Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Kelly Foley
- The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Graduate Program in Cellular and Molecular Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Pingbo Zhang
- Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Qian Xiao
- The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Jennifer Kleponis
- The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Annie A Wu
- The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Rajni Sharma
- Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Guanglan Mo
- The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,The Skip Viragh Center for Pancreatic Cancer, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Angen Liu
- The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Jennifer Van Eyk
- Department of Medicine, Biological Chemistry and Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Elizabeth M Jaffee
- The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Graduate Program in Cellular and Molecular Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,The Skip Viragh Center for Pancreatic Cancer, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Lei Zheng
- The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland. .,Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Graduate Program in Cellular and Molecular Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,The Skip Viragh Center for Pancreatic Cancer, The Johns Hopkins University School of Medicine, Baltimore, Maryland.,Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
42
|
Bullen JW, Tchernyshyov I, Holewinski RJ, DeVine L, Wu F, Venkatraman V, Kass DL, Cole RN, Van Eyk J, Semenza GL. Protein kinase A-dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1. Sci Signal 2016; 9:ra56. [PMID: 27245613 PMCID: PMC5541497 DOI: 10.1126/scisignal.aaf0583] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes encoding proteins that enable cells to adapt to reduced O2 availability. Proteins encoded by HIF-1 target genes play a central role in mediating physiological processes that are dysregulated in cancer and heart disease. These diseases are also characterized by increased production of cyclic adenosine monophosphate (cAMP), the allosteric activator of cAMP-dependent protein kinase A (PKA). Using glutathione S-transferase pull-down, coimmunoprecipitation, and mass spectrometry analyses, we demonstrated that PKA interacts with HIF-1α in HeLa cervical carcinoma cells and rat cardiomyocytes. PKA phosphorylated Thr(63) and Ser(692) on HIF-1α in vitro and enhanced HIF transcriptional activity and target gene expression in HeLa cells and rat cardiomyocytes. PKA inhibited the proteasomal degradation of HIF-1α in an O2-independent manner that required the phosphorylation of Thr(63) and Ser(692) and was not affected by prolyl hydroxylation. PKA also stimulated the binding of the coactivator p300 to HIF-1α to enhance its transcriptional activity and counteracted the inhibitory effect of asparaginyl hydroxylation on the association of p300 with HIF-1α. Furthermore, increased cAMP concentrations enhanced the expression of HIF target genes encoding CD39 and CD73, which are enzymes that convert extracellular adenosine 5'-triphosphate to adenosine, a molecule that enhances tumor immunosuppression and reduces heart rate and contractility. These data link stimuli that promote cAMP signaling, HIF-1α-dependent changes in gene expression, and increased adenosine, all of which contribute to the pathophysiology of cancer and heart disease.
Collapse
Affiliation(s)
- John W Bullen
- Vascular Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Irina Tchernyshyov
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Ronald J Holewinski
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Lauren DeVine
- Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Fan Wu
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Vidya Venkatraman
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - David L Kass
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Robert N Cole
- Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Jennifer Van Eyk
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Gregg L Semenza
- Vascular Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
| |
Collapse
|
43
|
Sohn DH, Rhodes C, Onuma K, Zhao X, Sharpe O, Gazitt T, Shiao R, Fert-Bober J, Cheng D, Lahey LJ, Wong HH, Van Eyk J, Robinson WH, Sokolove J. Local Joint inflammation and histone citrullination in a murine model of the transition from preclinical autoimmunity to inflammatory arthritis. Arthritis Rheumatol 2016; 67:2877-87. [PMID: 26227989 DOI: 10.1002/art.39283] [Citation(s) in RCA: 83] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 07/09/2015] [Indexed: 12/29/2022]
Abstract
OBJECTIVE Anti-citrullinated protein antibodies (ACPAs) are characteristic of rheumatoid arthritis (RA). However, their presence years before the onset of clinical RA is perplexing. Although multiple putative citrullinated antigens have been identified, no studies have demonstrated the specific capacity of these antigens to initiate inflammatory arthritis. This study was undertaken to recapitulate the transition from preclinical to clinical RA and to demonstrate the capacity of local citrullination to facilitate this transition. METHODS We performed proteomic analysis of activated human neutrophils to identify citrullinated proteins, including those targeted as part of the RA immune response. Using enzyme-linked immunosorbent assay, we compared RA and osteoarthritis synovial fluid for levels of citrullinated histone H2B and its immune complex. Using macrophage activation assays, we assessed the effect of histone citrullination on immunostimulatory capacity and evaluated the stimulatory capacity of native and citrullinated H2B immune complexes. Finally, we assessed the potential for anti-citrullinated H2B antibodies to mediate arthritis in vivo. RESULTS We identified robust targeting of neutrophil-derived citrullinated histones by the ACPA immune response. More than 90% of the RA patients had anti-citrullinated H2B antibodies. Histone citrullination increased innate immunostimulatory capacity, and immune complexes containing citrullinated histones activated macrophage cytokine production and propagated neutrophil activation. Finally, we demonstrated that immunization with H2B was arthritogenic, but only in the setting of underlying articular inflammation. CONCLUSION Our findings indicate that citrullinated histones, specifically citrullinated H2B, are an antigenic target of the ACPA immune response. Furthermore, local generation of citrullinated antigen during low-grade articular inflammation provides a mechanistic model for the conversion from preclinical autoimmunity to inflammatory arthritis.
Collapse
Affiliation(s)
- Dong Hyun Sohn
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| | - Christopher Rhodes
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| | - Kazuhiro Onuma
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| | - Xiaoyan Zhao
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| | - Orr Sharpe
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| | - Tal Gazitt
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| | - Rani Shiao
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| | | | - Danye Cheng
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| | - Lauren J Lahey
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| | - Heidi H Wong
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| | | | - William H Robinson
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| | - Jeremy Sokolove
- VA Palo Alto Healthcare System, Palo Alto, California, and Stanford University School of Medicine, Stanford, California
| |
Collapse
|
44
|
Kaushik G, Van Eyk J, Cammarato A, Engler A. Vinculin Remodeling of the Sarcomere Lattice Regulates Contractile Function. Biophys J 2016. [DOI: 10.1016/j.bpj.2015.11.567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
45
|
Ping P, Gustafsson ÅB, Bers DM, Blatter LA, Cai H, Jahangir A, Kelly D, Muoio D, O'Rourke B, Rabinovitch P, Trayanova N, Van Eyk J, Weiss JN, Wong R, Schwartz Longacre L. Harnessing the Power of Integrated Mitochondrial Biology and Physiology: A Special Report on the NHLBI Mitochondria in Heart Diseases Initiative. Circ Res 2015; 117:234-8. [PMID: 26185209 DOI: 10.1161/circresaha.117.306693] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Mitochondrial biology is the sum of diverse phenomena from molecular profiles to physiological functions. A mechanistic understanding of mitochondria in disease development, and hence the future prospect of clinical translations, relies on a systems-level integration of expertise from multiple fields of investigation. Upon the successful conclusion of a recent National Institutes of Health, National Heart, Lung, and Blood Institute initiative on integrative mitochondrial biology in cardiovascular diseases, we reflect on the accomplishments made possible by this unique interdisciplinary collaboration effort and exciting new fronts on the study of these remarkable organelles.
Collapse
Affiliation(s)
- Peipei Ping
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Åsa B Gustafsson
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Don M Bers
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Lothar A Blatter
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Hua Cai
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Arshad Jahangir
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Daniel Kelly
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Deborah Muoio
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Brian O'Rourke
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Peter Rabinovitch
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Natalia Trayanova
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Jennifer Van Eyk
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - James N Weiss
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Renee Wong
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.)
| | - Lisa Schwartz Longacre
- From the Departments of Physiology and Medicine, UCLA David Geffen School of Medicine (P.P., H.C., J.N.W.); Department of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla (Å.B.G.); Department of Pharmacology, UC Davis, Davis, CA (D.M.B.); Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, IL (L.A.B.); Center for Integrative Research on Cardiovascular Aging, Cardiovascular Services and Department of Research, Aurora Health Care, Milwaukee, WI (A.J.); Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL (D.K.); Department of Medicine, Duke University, Durham, NC (D.M.); Department of Medicine, Division of Cardiology (B.O.R.), Department of Biomedical Engineering (N.T.), and Department of Medicine, Division of Cardiology (J.V.E.), The Johns Hopkins University School of Medicine, Baltimore, MD (B.O'R., N.T., J.V.E.); Department of Pathology, University of Washington, Seattle (P.R.); and Heart Failure and Arrhythmia Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.W., L.S.L.).
| |
Collapse
|
46
|
Korley FK, Diaz-Arrastia R, Wu AHB, Yue JK, Manley GT, Sair HI, Van Eyk J, Everett AD, Okonkwo DO, Valadka AB, Gordon WA, Maas AIR, Mukherjee P, Yuh EL, Lingsma HF, Puccio AM, Schnyer DM. Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury. J Neurotrauma 2015; 33:215-25. [PMID: 26159676 DOI: 10.1089/neu.2015.3949] [Citation(s) in RCA: 99] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Brain-derived neurotrophic factor (BDNF) is important for neuronal survival and regeneration. We investigated the diagnostic and prognostic values of serum BDNF in traumatic brain injury (TBI). We examined serum BDNF in two independent cohorts of TBI cases presenting to the emergency departments (EDs) of the Johns Hopkins Hospital (JHH; n = 76) and San Francisco General Hospital (SFGH, n = 80), and a control group of JHH ED patients without TBI (n = 150). Findings were subsequently validated in the prospective, multi-center Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Pilot study (n = 159). We investigated the association between BDNF, glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1) and recovery from TBI at 6 months in the TRACK-TBI Pilot cohort. Incomplete recovery was defined as having either post-concussive syndrome or a Glasgow Outcome Scale Extended score <8 at 6 months. Median day-of-injury BDNF concentrations (ng/mL) were lower among TBI cases (JHH TBI, 17.5 and SFGH TBI, 13.8) than in JHH controls (60.3; p = 0.0001). Among TRACK-TBI Pilot subjects, median BDNF concentrations (ng/mL) were higher in mild (8.3) than in moderate (4.3) or severe TBI (4.0; p = 0.004. In the TRACK-TBI cohort, the 75 (71.4%) subjects with very low BDNF values (i.e., <the 1st percentile for non-TBI controls, <14.2 ng/mL) had higher odds of incomplete recovery than those who did not have very low values (odds ratio, 4.0; 95% confidence interval [CI]: 1.5-11.0). The area under the receiver operator curve for discriminating complete and incomplete recovery was 0.65 (95% CI: 0.52-0.78) for BDNF, 0.61 (95% CI: 0.49-0.73) for GFAP, and 0.55 (95% CI: 0.43-0.66) for UCH-L1. The addition of GFAP/UCH-L1 to BDNF did not improve outcome prediction significantly. Day-of-injury serum BDNF is associated with TBI diagnosis and also provides 6-month prognostic information regarding recovery from TBI. Thus, day-of-injury BDNF values may aid in TBI risk stratification.
Collapse
Affiliation(s)
- Frederick K Korley
- 1 Department of Emergency Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland
| | - Ramon Diaz-Arrastia
- 2 Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences , Bethesda, Maryland
| | - Alan H B Wu
- 3 Clinical Chemistry Laboratory, San Francisco General Hospital , San Francisco, California
| | - John K Yue
- 4 Department of Neurological Surgery, University of California San Francisco , San Francisco, California
| | - Geoffrey T Manley
- 4 Department of Neurological Surgery, University of California San Francisco , San Francisco, California
| | - Haris I Sair
- 5 Department of Radiology, Johns Hopkins University School of Medicine , Baltimore, Maryland
| | - Jennifer Van Eyk
- 6 Department of Medicine, the Advanced Clinical Biosystems Research Institute , Cedars Sinai Medical Center, Los Angeles, California
| | - Allen D Everett
- 7 Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, Maryland
| | | | - David O Okonkwo
- 8 The Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Investigators .,9 Department of Neurological Surgery, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania
| | - Alex B Valadka
- 8 The Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Investigators .,10 Seton Brain and Spine Institute , Austin, Texas
| | - Wayne A Gordon
- 8 The Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Investigators .,11 Department of Rehabilitation Medicine, Mount Sinai School of Medicine , New York, New York
| | - Andrew I R Maas
- 8 The Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Investigators .,12 Department of Neurosurgery, Antwerp University Hospital , Edegem, Belgium
| | - Pratik Mukherjee
- 8 The Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Investigators .,13 Department of Radiology and Biomedical Imaging University of California San Francisco , San Francisco, California
| | - Esther L Yuh
- 8 The Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Investigators .,13 Department of Radiology and Biomedical Imaging University of California San Francisco , San Francisco, California
| | - Hester F Lingsma
- 8 The Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Investigators .,14 Department of Public Health Center for Medical Decision Making Erasmas Medical Center , Rotterdam, the Netherlands
| | - Ava M Puccio
- 8 The Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Investigators .,9 Department of Neurological Surgery, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania
| | - David M Schnyer
- 8 The Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Investigators .,15 Department of Psychology, University of Texas , Austin, Texas
| |
Collapse
|
47
|
Agrawal S, Van Eyk J, Sobhani K, Wei J, Bairey Merz CN. Sex, Myocardial Infarction, and the Failure of Risk Scores in Women. J Womens Health (Larchmt) 2015; 24:859-61. [PMID: 26288193 DOI: 10.1089/jwh.2015.5412] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Affiliation(s)
- Shilpa Agrawal
- 1 David Geffen School of Medicine, University of California Los Angeles , Los Angeles, California
| | - Jennifer Van Eyk
- 2 Barbra Streisand Women's Heart Center, Cedars-Sinai Heart Institute , Cedars-Sinai Medical Center, Los Angeles, California
| | - Kimia Sobhani
- 3 Pathology and Laboratory Medicine, Cedars-Sinai Heart Institute , Cedars-Sinai Medical Center, Los Angeles, California
| | - Janet Wei
- 1 David Geffen School of Medicine, University of California Los Angeles , Los Angeles, California
| | - C Noel Bairey Merz
- 2 Barbra Streisand Women's Heart Center, Cedars-Sinai Heart Institute , Cedars-Sinai Medical Center, Los Angeles, California
| |
Collapse
|
48
|
Lindsey ML, Mayr M, Gomes AV, Delles C, Arrell DK, Murphy AM, Lange RA, Costello CE, Jin YF, Laskowitz DT, Sam F, Terzic A, Van Eyk J, Srinivas PR. Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association. Circulation 2015. [PMID: 26195497 DOI: 10.1161/cir.0000000000000226] [Citation(s) in RCA: 125] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The year 2014 marked the 20th anniversary of the coining of the term proteomics. The purpose of this scientific statement is to summarize advances over this period that have catalyzed our capacity to address the experimental, translational, and clinical implications of proteomics as applied to cardiovascular health and disease and to evaluate the current status of the field. Key successes that have energized the field are delineated; opportunities for proteomics to drive basic science research, facilitate clinical translation, and establish diagnostic and therapeutic healthcare algorithms are discussed; and challenges that remain to be solved before proteomic technologies can be readily translated from scientific discoveries to meaningful advances in cardiovascular care are addressed. Proteomics is the result of disruptive technologies, namely, mass spectrometry and database searching, which drove protein analysis from 1 protein at a time to protein mixture analyses that enable large-scale analysis of proteins and facilitate paradigm shifts in biological concepts that address important clinical questions. Over the past 20 years, the field of proteomics has matured, yet it is still developing rapidly. The scope of this statement will extend beyond the reaches of a typical review article and offer guidance on the use of next-generation proteomics for future scientific discovery in the basic research laboratory and clinical settings.
Collapse
|
49
|
Srivastava V, Tchernyshyov I, Van Eyk J, Robinson DN. The Dynamic Interplay between Cleavage Furrow Proteins in Cellular Mechanoresponsiveness. Biophys J 2015. [DOI: 10.1016/j.bpj.2014.11.3084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
50
|
Van Eyk J. Prof. Michael (Mike) J. Dunn - Paying Forward. Proteomics Clin Appl 2014; 8:476. [DOI: 10.1002/prca.201470045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|